Unknown

Dataset Information

0

Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.


ABSTRACT: AVAGAST was an international, randomized, placebo-controlled phase III study of chemotherapy with or without bevacizumab as first-line therapy for patients with advanced gastric cancer. We performed exploratory analyses to evaluate regional differences observed in the trial.Analyses were performed in the placebo plus chemotherapy arm (intention-to-treat population). Chemotherapy was cisplatin 80 mg/m2 for six cycles plus capecitabine (1000 mg/m2 orally bid days 1-14) or 5-fluorouracil (800 mg/m2/day continuous IV infusion days 1-5) every 3 weeks until disease progression or unacceptable toxicity.Overall, 387 patients were assigned to placebo plus chemotherapy (eastern Europe/South America, n = 118; USA/western Europe, n = 81; Korea/other Asia, n = 94; Japan, n = 94). At baseline, poor performance status, liver metastases, and larger tumors were most frequent in eastern Europe/South America and least frequent in Japan. Patients received subsequent chemotherapy after disease progression as follows: eastern Europe/South America (14%); USA/western Europe (37%); Korea/other Asia (61%); and Japan (77%). Hazard ratios for overall survival versus USA/western Europe were 1.47 (95% CI, 1.09-1.99) for eastern Europe/South America, 0.91 (95% CI, 0.67-1.25) for Korea/other Asia, and 0.87 (95% CI, 0.64-1.19) for Japan.Regional differences in the healthcare environment may have contributed to the differences in overall survival observed in the AVAGAST study.

SUBMITTER: Sawaki A 

PROVIDER: S-EPMC5906488 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm.

Sawaki Akira A   Yamada Yasuhide Y   Yamaguchi Kensei K   Nishina Tomohiro T   Doi Toshihiko T   Satoh Taroh T   Chin Keisho K   Boku Narikazu N   Omuro Yasushi Y   Komatsu Yoshito Y   Hamamoto Yasuo Y   Koizumi Wasaburo W   Saji Shigehira S   Shah Manish A MA   Van Cutsem Eric E   Kang Yoon-Koo YK   Iwasaki Junko J   Kuriki Hiroshi H   Ohtsuka Wataru W   Ohtsu Atsushi A  

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20171020 3


<h4>Background</h4>AVAGAST was an international, randomized, placebo-controlled phase III study of chemotherapy with or without bevacizumab as first-line therapy for patients with advanced gastric cancer. We performed exploratory analyses to evaluate regional differences observed in the trial.<h4>Methods</h4>Analyses were performed in the placebo plus chemotherapy arm (intention-to-treat population). Chemotherapy was cisplatin 80 mg/m<sup>2</sup> for six cycles plus capecitabine (1000 mg/m<sup>2  ...[more]

Similar Datasets

| S-EPMC7607108 | biostudies-literature
| EGAD00010002325 | EGA
| S-EPMC7930411 | biostudies-literature
| S-EPMC8146574 | biostudies-literature
2014-06-30 | E-GEOD-57176 | biostudies-arrayexpress
| S-EPMC5019744 | biostudies-literature
| S-EPMC8411394 | biostudies-literature
| S-EPMC4075047 | biostudies-literature
| S-EPMC4664910 | biostudies-other
2014-06-30 | GSE57176 | GEO